Sino Biopharmaceutical マネジメント

マネジメント基準チェック /14

Sino Biopharmaceuticalの CEO はEric S. Y. Tseで、 Jul2022年に任命され、の在任期間は 2.42年です。の年間総報酬はCN¥ 49.69Mで、 45.4%給与と54.6%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の22.27%を直接所有しており、その価値はHK$ 13.06B 。経営陣と取締役会の平均在任期間はそれぞれ1.9年と9.6年です。

主要情報

Eric S. Y. Tse

最高経営責任者

CN¥49.7m

報酬総額

CEO給与比率	45.4%
CEO在任期間	2.4yrs
CEOの所有権	22.3%
経営陣の平均在職期間	1.9yrs
取締役会の平均在任期間	9.6yrs

経営陣の近況

Recent updates

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Dec 08

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

Oct 02

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Apr 21

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Apr 03

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Mar 20

CEO報酬分析

Sino Biopharmaceutical の収益と比較して、Eric S. Y. Tse の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	CN¥2b
Mar 31 2024	n/a	n/a	CN¥2b
Dec 31 2023	CN¥50m	CN¥23m	CN¥2b
Jun 30 2023	n/a	n/a	CN¥1b
Mar 31 2023	n/a	n/a	CN¥2b
Dec 31 2022	n/a	n/a	CN¥2b
Sep 30 2022	n/a	n/a	CN¥5b
Jun 30 2022	n/a	n/a	CN¥8b
Mar 31 2022	n/a	n/a	CN¥14b
Dec 31 2021	CN¥23m	CN¥6m	CN¥15b
Sep 30 2021	n/a	n/a	CN¥12b
Jun 30 2021	n/a	n/a	CN¥10b
Mar 31 2021	n/a	n/a	CN¥4b
Dec 31 2020	CN¥25m	CN¥7m	CN¥3b
Sep 30 2020	n/a	n/a	CN¥2b
Jun 30 2020	n/a	n/a	CN¥3b
Mar 31 2020	n/a	n/a	CN¥3b
Dec 31 2019	CN¥6m	CN¥870k	CN¥3b

報酬と市場: Eric S. Y.の総報酬 ($USD 6.81M ) は、 Hong Kong市場 ($USD 848.16K ) の同規模の企業の平均を上回っています。

報酬と収益: Eric S. Y.の報酬は過去 1 年間で 20% 以上増加しました。

CEO（最高経営責任者

Eric S. Y. Tse (28 yo)

2.4yrs

在職期間

CN¥49,691,000

報酬

Mr. Eric S. Y. Tse serves as an Executive Director at Sino Biopharmaceutical Limited since October 23, 2019 and serves as its Chief Executive Officer since July 28, 2022. Mr. Tse joined Sino Biopharmaceuti...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Y. Y. Tse	Executive Chairwoman of the Board	9.5yrs	CN¥49.69m	0.033% HK$ 19.3m
Eric S. Y. Tse	CEO & Executive Director	2.4yrs	CN¥49.69m	22.27% HK$ 13.1b
Ping Tse	Founder & Senior Executive Vice Chairman	4.3yrs	CN¥49.53m	9.11% HK$ 5.3b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.7yrs	CN¥43.13m	16.31% HK$ 9.6b
Zhoushan Tian	Executive Director	no data	CN¥1.91m	データなし
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.96% HK$ 1.2b
Chun Ling Li	Chief Financial Officer	1.9yrs	データなし	データなし
Song Jin	Vice President of Public Affairs	no data	データなし	データなし
Sean Chen	Chief Strategy Officer	1.9yrs	データなし	データなし
Chau Ling Yu	Assistant VP & Financial Controller	no data	データなし	データなし
Oi Nin Chan	Company Secretary	9.3yrs	データなし	データなし
Toogood Ben	CEO of invoX & Head of Globalization	1.9yrs	データなし	データなし

1.9yrs

平均在職期間

53yo

平均年齢

経験豊富な経営陣: 1177の経営陣は経験豊富とはみなされません ( 1.9年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Y. Y. Tse	Executive Chairwoman of the Board	9.5yrs	CN¥49.69m	0.033% HK$ 19.3m
Eric S. Y. Tse	CEO & Executive Director	5.2yrs	CN¥49.69m	22.27% HK$ 13.1b
Ping Tse	Founder & Senior Executive Vice Chairman	4.3yrs	CN¥49.53m	9.11% HK$ 5.3b
Cheung Ling Cheng	Executive Vice Chairwoman of the Board	7.7yrs	CN¥43.13m	16.31% HK$ 9.6b
Zhoushan Tian	Executive Director	9.7yrs	CN¥1.91m	データなし
Hsin Tse	Senior VP & Executive Director	no data	CN¥6.41m	1.96% HK$ 1.2b
Zhengfei Lu	Independent Non-Executive Director	19.1yrs	CN¥376.00k	データなし
Dakui Li	Independent Non-Executive Director	20.3yrs	CN¥376.00k	データなし
Lu Fu Zhang	Independent Non-Executive Director	9.7yrs	CN¥376.00k	データなし
Hong Lu	Independent Non-Executive Director	9.7yrs	CN¥342.00k	データなし
Kwok Tung Li	Independent Non-Executive Director	4yrs	CN¥376.00k	0.00039% HK$ 228.6k

9.6yrs

平均在職期間

60yo

平均年齢

経験豊富なボード: 1177の取締役会は経験豊富であると考えられます ( 9.6年の平均在任期間)。

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2024/12/23 18:45
終値	2024/12/23 00:00
収益	2024/06/30
年間収益	2023/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を例とし、非米国証券については同等の規制書式と情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Sino Biopharmaceutical Limited 23 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。51

アナリスト	機関
Justin Liu	BNP Paribas Securities (Asia)
Ling Zhang	BNP Paribas Securities (Asia)
Wai Chak Yuen	BOCI Research Ltd.

Sino Biopharmaceutical マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Key Executive recently sold HK$51m worth of stock

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Key Executive recently bought HK$34m worth of stock

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

Recent updates

Sino Biopharmaceutical Limited Obtains Permission to Submit Marketing Application for Indication of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for Treatment of Advanced Alveolar Soft Part Sarcoma

Sino Biopharmaceutical Limited Announces Positive Results from Phase III Study of Benmelstobart Injection with or Without Anlotinib Hydrochloride Capsules as Consolidation Therapy After Chemoradiotherapy for Non-Small Cell Lung Cancer

Sino Biopharmaceutical Limited Announces Approval for Marketing of Eribulin Mesilate Injection

Is Sino Biopharmaceutical (HKG:1177) A Risky Investment?

Sino Biopharmaceutical Limited Announces Approval for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for the Indication of Treatment for Endometrial Cancer

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsule in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Carcinoma

Sino Biopharmaceutical Limited Announces Approval for Clinical Trials of the Fourth-Generation EGFR Inhibitor "TQB3002" in the United States

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Anlotinib Hydrochloride Capsules in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Key Executive recently sold HK$51m worth of stock

After Leaping 27% Sino Biopharmaceutical Limited (HKG:1177) Shares Are Not Flying Under The Radar

First half 2024 earnings: EPS and revenues exceed analyst expectations

Sino Biopharmaceutical Limited Announces Phase III Study Results of Culmerciclib in Combination with Fulvestrant for Treatment of HR+/HER2- Advanced Breast Cancer Following Endocrine Treatment Presented At 2024 CSCO

Sino Biopharmaceutical Limited Announces Phase III Study Results of Anlotinib Hydrochloride Capsules in Combination with Penpulimab Injection for First-Line Treatment of Advanced Hepatocellular Cancinoma Was Presented at ESMO 2024

Upcoming dividend of HK$0.03 per share

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Penpulimab for First-Line Treatment of Advanced Hepatocellular Carcoma

Consensus EPS estimates increase by 11%

First half 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.068 in 1H 2023)

Sino Biopharmaceutical Limited Announces Acceptance of New Indication Application for Marketing of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsule for First-Line Treatment of Advanced Renal Cell Carinoma

Sino Biopharmaceutical Limited to Report Q2, 2024 Results on Aug 13, 2024

Sino Biopharmaceutical Limited Announces Interim Analysis of Phase III Clinical Trial of the Categroy 1 Innovative Drug Culmerciclib Capsule

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Anlotinib Hydrochloride Capsule in Combination with Chemotherapy for First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Acceptance of New Drug Application for Categroy 1 Innovative Drug Rovadicitinib Tablet

Are Investors Undervaluing Sino Biopharmaceutical Limited (HKG:1177) By 48%?

Sino Biopharmaceutical Limited Receives Approval for Marketing of Liraglutide Injection

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Innovative Drug Envonalkib Citrate Capsules "Envonalkib (TQ-B3139)"

Sino Biopharmaceutical Limited Announces Approval for Marketing of Gadoteridol Injection

Sino Biopharmaceutical Limited Announces Retirement of Ms. Li Mingqin as Executive Director

Upcoming dividend of HK$0.03 per share

Sino Biopharmaceutical Limited Announces Positive Results on Phase III Study of Benmelstobart Injection in Combination with Anlotinib Hydrochloride Capsules for First-Line Treatment of Advanced Renal Cell Carcinoma

Here's Why Sino Biopharmaceutical (HKG:1177) Can Manage Its Debt Responsibly

Sino Biopharmaceutical Limited Receives Marketing Approval from National Medical Products Administration of China

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Announces Approval for Marketing of Category 1 Unecritinib Fumarate Capsules

Investor sentiment improves as stock rises 18%

Executive Chairwoman of the Board recently bought HK$5.8m worth of stock

Sino Biopharmaceutical Limited's (HKG:1177) 27% Cheaper Price Remains In Tune With Earnings

Consensus revenue estimates fall by 13%

What Does The Future Hold For Sino Biopharmaceutical Limited (HKG:1177)? These Analysts Have Been Cutting Their Estimates

Sino Biopharmaceutical Limited, Annual General Meeting, Jun 05, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Sino Biopharmaceutical Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 5 July 2024

Sino Biopharmaceutical Limited's (HKG:1177) Intrinsic Value Is Potentially 34% Above Its Share Price

Sino Biopharmaceutical Limited Provides Update on Development Progress of Mash Products "Lanifibranor" and "TQA2225"

Sino Biopharmaceutical Limited Announces Latest Results of Phase II Clinical Study of KRAS G12C Inhibitor Garsorasib Tablet

Sino Biopharmaceutical Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Sino Biopharmaceutical Limited Announces Acceptance of the New Indication Application for Marketing of Anlotinib Hydrochloride Capsules and Anti Pd-L1 Benmelstobart

Qingdao Ocean Innovative Products Investment Fund Co., Ltd. and Qingdao Ocean New Kinetic Energy Products Investment Fund (Limited Partnership) agreed to acquire 67% stake in CP Pharmaceutical (Qingdao) Co., Ltd from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 1.8 billion.

Sino Biopharmaceutical Limited Announces Prioritised Evaluation Granted for KRAS G12c Inhibitor Garsorasib Tablet (D-1553)

Now 21% undervalued

Sino Biopharmaceutical Limited Announces Approval of Clinical Trial for Neuropathic Pain

Sino Biopharmaceutical Limited Announces Completion of Patient Enrollment in Phase III Clinical Trial of Anlotinib Combined with Chemotherapy in First-Line Treatment of Advanced Soft Tissue Sarcoma

Sino Biopharmaceutical Limited Announces Phase I Clinical Research Results of Tqh2722

Sino Biopharmaceutical Limited Announces First Dose of the First Batch of Subjects in Phase I Clinical Trial of TQA3038

An unknown buyer acquired Suzhou Tianqing Xingwei Med./Lianyungang Chia Tai Tianqing Med./Zhejia Tianqing Zhongwei Med. from Sino Biopharmaceutical Limited (SEHK:1177) for approximately CNY 150 million.

Investor sentiment improves as stock rises 16%

Sino Biopharmaceutical Limited Announces Application for Phase Ib/II Clinical Trial of Innovative Drug

An unknown buyer acquired 84.2% stake in Shanghai Chia Tai Tongyong Pharmaceutical Co., Ltd. from Sino Biopharmaceutical Limited (SEHK:1177) for CNY 290 million.

Upcoming dividend of HK$0.02 per share at 2.7% yield

Sino Biopharmaceutical Limited Announces IND Application of Innovative Medicine TRD205 (AT2R Antibody) Filed with and Accept by FDA

First half 2023 earnings released: EPS: CN¥0.068 (vs CN¥0.10 in 1H 2022)

Sino Biopharmaceutical Limited Announces Interim Cash Dividend for the Period Ended 30 June 2023, Payable on 27 October 2023

Sino Biopharmaceutical Limited to Report First Half, 2023 Results on Aug 25, 2023

Key Executive recently bought HK$34m worth of stock

Sino Biopharmaceutical Limited Announces Application for Marketing of Loxoprofen Sodium Cataplasms

Upcoming dividend of HK$0.06 per share at 3.0% yield

Sino Biopharmaceutical Limited Announces New Drug Marketing Application for the Category 1 Innovative Anti-Tumor Medicine

Sino Biopharmaceutical Limited Announces Approval for Marketing by National Medical Products Administration of China for F-627 (Efbemalenograstim alfa Injection)

Executive Vice Chairwoman of the Board recently bought HK$21m worth of stock

マネジメント基準チェック /14